|
1
|
Manns MP, Czaja AJ, Gorham JD, Krawitt EL,
Mieli-Vergani G, Vergani D and Vierling JM: American Association
for the Study of Liver Diseases: Diagnosis and management of
autoimmune hepatitis. Hepatology. 51:2193–2213. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heneghan MA, Yeoman AD, Verma S, Smith AD
and Longhi MS: Autoimmune hepatitis. Lancet. 382:1433–1444. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gleeson D and Heneghan MA: British Society
of Gastroenterology: British Society of Gastroenterology (BSG)
guidelines for management of autoimmune hepatitis. Gut.
60:1611–1629. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Selvarajah V, Montano-Loza AJ and Czaja
AJ: Systematic review: Managing suboptimal treatment responses in
autoimmune hepatitis with conventional and nonstandard drugs.
Aliment Pharmacol Ther. 36:691–707. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zachou K, Gatselis N, Papadamou G,
Rigopoulou EI and Dalekos GN: Mycophenolate for the treatment of
autoimmune hepatitis: Prospective assessment of its efficacy and
safety for induction and maintenance of remission in a large cohort
of treatment-naïve patients. J Hepatol. 55:636–646. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Czaja AJ, Wang KK, Shiels MT and Katzmann
JA: Oral pulse prednisone therapy after relapse of severe
autoimmune chronic active hepatitis. A prospective randomized
treatment trial evaluating clinical, biochemical, and lymphocyte
subset responses. J Hepatol. 17:180–186. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Czaja AJ, Carpenter HA and Lindor KD:
Ursodeoxycholic acid as adjunctive therapy for problematic type 1
autoimmune hepatitis: A randomized placebo-controlled treatment
trial. Hepatology. 30:1381–1386. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Van Thiel DH, Wright H, Carroll P,
Abu-Elmagd K, Rodriguez-Rilo H, McMichael J, Irish W and Starzl TE:
Tacrolimus: A potential new treatment for autoimmune chronic active
hepatitis: Results of an open-label preliminary trial. Am J
Gastroenterol. 90:771–776. 1995.PubMed/NCBI
|
|
9
|
Cook GC, Mulligan R and Sherlock S:
Controlled prospective trial of corticosteroid therapy in active
chronic hepatitis. Q J Med. 40:159–185. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soloway RD, Summerskill WH, Baggenstoss
AH, Geall MG, Gitnićk GL, Elveback IR and Schoenfield LJ: Clinical,
biochemical, and histological remission of severe chronic active
liver disease: A controlled study of treatments and early
prognosis. Gastroenterology. 63:820–833. 1972.PubMed/NCBI
|
|
11
|
Murray-Lyon IM, Stern RB and Williams R:
Controlled trial of prednisone and azathioprine in active chronic
hepatitis. Lancet. 1:735–737. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Summerskill WH, Korman MG, Ammon HV and
Baggenstoss AH: Prednisone for chronic active liver disease: Dose
titration, standard dose, and combination with azathioprine
compared. Gut. 16:876–883. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tage-Jensen U, Schlichting P, Aldershvile
J, Andersen P, Dietrichson O, Hardt F, Mathiesen LR and Nielsen JO:
Azathioprine versus prednisone in non-alcoholic chronic liver
disease (CLD). Relation to a serological classification. Liver.
2:95–103. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Manns MP, Woynarowski M, Kreisel W, Lurie
Y, Rust C, Zuckerman E, Bahr MJ, Günther R, Hultcrantz RW, Spengler
U, et al: Budesonide induces remission more effectively than
prednisone in a controlled trial of patients with autoimmune
hepatitis. Gastroenterology. 139:1198–1206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nasseri-Moghaddam S, Nikfam S, Karimian S,
Khashayar P and Malekzadeh R: Cyclosporine-a versus prednisolone
for induction of remission in auto-immune hepatitis: Interim
analysis report of a randomized controlled trial. Middle East J Dig
Dis. 5:193–200. 2013.PubMed/NCBI
|
|
16
|
Boberg KM, Aadland E, Jahnsen J, Raknerud
N, Stiris M and Bell H: Incidence and prevalence of primary biliary
cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis
in a Norwegian population. Scand J Gastroenterol. 33:99–103. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Werner M, Prytz H, Ohlsson B, Almer S,
Björnsson E, Bergquist A, Wallerstedt S, Sandberg-Gertzén H,
Hultcrantz R, Sangfelt P, et al: Epidemiology and the initial
presentation of autoimmune hepatitis in Sweden: A nationwide study.
Scand J Gastroenterol. 43:1232–1240. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Caldwell DM, Ades AE and Higgins JP:
Simultaneous comparison of multiple treatments: Combining direct
and indirect evidence. BMJ. 331:897–900. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Johnson PJ and Mcfarlane IG: Meeting
report: International Autoimmune Hepatitis Group. Hepatology.
18:998–1005. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Higgins JP, Altman DG, Gøtzsche PC, Jüni
P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L and Sterne JA:
Cochrane Bias Methods Group; Cochrane Statistical Methods Group:
The cochrane collaboration's tool for assessing risk of bias in
randomised trials. BMJ. 343:d59282011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chaimani A, Higgins JP, Mavridis D,
Spyridonos P and Salanti G: Graphical tools for network
meta-analysis in STATA. PLoS One. 8:e766542013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen LX, Li YL, Ning GZ, Li Y, Wu QL, Guo
JX, Shi HY, Wang XB, Zhou Y and Feng SQ: Comparative efficacy and
tolerability of three treatments in old people with osteoporotic
vertebral compression fracture: A network meta-analysis and
systematic review. PLoS One. 10:e01231532015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sogo T, Fujisawa T, Inui A, Komatsu H,
Etani Y, Tajiri H, Waki K, Shimizu Y, Nakashima S, Imagawa T and
Yokota S: Intravenous methylprednisolone pulse therapy for children
with autoimmune hepatitis. Hepatol Res. 34:187–192. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Woynarowski M, Nemeth A, Baruch Y,
Koletzko S, Melter M, Rodeck B, Strassburg CP, Pröls M, Woźniak M
and Manns MP: European Autoimmune Hepatitis-Budesonide Study Group:
Budesonide versus prednisone with azathioprine for the treatment of
autoimmune hepatitis in children and adolescents. J Pediatr.
163:1347–1353.e1. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cuarterolo M, Ciocca M, López S, López V,
Araujo M and Alvarez F: Initial treatment of autoimmune hepatitis
in children: Neoral cyclosporine versus prednisone plus
azathioprine. J Pediat Gastroenterol Nutr. 63:S562016.
|
|
26
|
Waisbourd-Zinman O, Hilmara D, Lin HC and
Rand E: Steroid free treatment of autoimmune hepatitis in selected
children. Hepatol. 63:354A–355A. 2016.
|
|
27
|
Stern RB, Wilkinson SP, Howorth PJ and
Williams R: Controlled trial of synthetic D-penicillamine and
prednisone in maintenance therapy for active chronic hepatitis.
Gut. 18:19–22. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hegarty JE, Aria Nouri KT, Eddleston AL
and Williams R: Controlled trial of a thymic hormone extract
(Thymostimulin) in ‘autoimmune’ chronic active hepatitis. Gut.
25:279–283. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Stellon AJ, Hegarty JE, Portmann B and
Williams R: Randomised controlled trial of azathioprine withdrawal
in autoimmune chronic active hepatitis. Lancet. 1:668–670. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stellon AJ, Keating JJ, Johnson PJ,
McFarlane IG and Williams R: Maintenance of remission in autoimmune
chronic active hepatitis with azathioprine after corticosteroid
withdrawal. Hepatology. 8:781–784. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mucenic M, Mello ES and Cançado EL:
Chloroquine for the maintenance of remission of autoimmune
hepatitis: Results of a pilot study. Arq Gastroenterol. 42:249–255.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chi XL, Xiao HM, Xie YB, Cai GS, Jiang JM,
Tian GJ, Shi MJ, Wu SD, Zhao PT and Chen HJ: Protocol of a
prospective study for the combination treatment of Shu-Gan-jian-Pi
decoction and steroid standard therapy in autoimmune hepatitis
patients. BMC Complement Altern Med. 16:5052016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cai X, Weng HH and Miao LY: Yinzhihuang
injection for treatment of patients with autoimmune hepatitis:
Clinical efficacy and impact on hepatic fibrosis indexes. World
Chin J Digestol. 25:726–731. 2017. View Article : Google Scholar
|
|
34
|
Imanieh MH, Khatami G and Ghavanini AA:
Comparison of prednisolone alone and in combination with
azathioprine regimens in treatment of autoimmune hepatitis: A
prospective study. Iranian J Med Sci. 25:67–71. 2000.
|
|
35
|
Gleeson D: Standard treatment in adults:
Which steroid? Or without steroids? Digest Dis (Basel,
Switzerland). 33 Suppl 2:S75–S82. 2015. View Article : Google Scholar
|
|
36
|
Cropley A and Weltman M: The use of
immunosuppression in autoimmune hepatitis: A current literature
review. Clin Mol Hepatol. 23:22–26. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Czaja AJ: Current and future treatments of
autoimmune hepatitis. Expert Rev Gastroenterol Hepatol. 3:269–291.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Czaja AJ: Drug choices in autoimmune
hepatitis: Part A-steroids. Expert Rev Gastroenterol Hepatol.
6:603–615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Czaja AJ: Nonstandard drugs and feasible
new interventions for autoimmune hepatitis: Part I. Inflamm Allergy
Drug Targets. 11:337–350. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Czaja AJ and Lindor KD: Failure of
budesonide in a pilot study of treatment-dependent autoimmune
hepatitis. Gastroenterology. 119:1312–1316. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Peiseler M, Liebscher T, Pannicke N,
Sebode M, Zenouzi R, Hartl J, Ehlken H, Weiler-Normann C, Lohse AW
and Schramm C: Budesonide for autoimmune hepatitis: Response rate
and limitations in a large real life cohort. J hepatol. 62 Suppl
2:S2332015. View Article : Google Scholar
|
|
42
|
Danielsson A and Prytz H: Oral budesonide
for treatment of autoimmune chronic active hepatitis. Aliment
Pharmacol Ther. 8:585–590. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Czaja AJ: Current and prospective
pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother.
15:1715–1736. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Anderka MT, Lin AE, Abuelo DN, Mitchell AA
and Rasmussen SA: Reviewing the evidence for mycophenolate mofetil
as a new teratogen: Case report and review of the literature. Am J
Med Genet A. 149A:1241–1248. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Efe C, Hagström H, Bhanji RA, Müller NF,
Wang Q, Purnak T, Muratori L, Werner M, Marschall HU, Muratori P,
et al: Tacrolimus or mycophenylate mofetil as a second-line
therapeutic options in patients with Autoimmune Hepatitis: An
international multicentre observational study. AASLD.
62:1095522015.
|
|
46
|
Zachou K, Gatselis N, Gabeta S, Saitis A,
Koukoulis G and Dalekos GN: P1138: Long-term outcome of patients
with autoimmune hepatitis receiving mycophenolate mofetil (MMF) as
first line treatment. J Hepatol. 62 Suppl 2:S778–S779. 2015.
View Article : Google Scholar
|
|
47
|
Gazzola A, Lim R, Strasser S, Nicoll A,
Mitchell J, Siow W, Khoo T, Hamarneh Z, Weltman M, Janko N, et al:
Mycophenolate in autoimmune hepatitis not responsive or intolerant
to standard therapy: The TAPESTRY study. J Gastroenterol Hepatol
(Australia). 31:100–101. 2016.
|
|
48
|
Gazzola A, Lim R, Strasser SI, Nicoll A,
Mitchell J, Siow W, Khoo TS, Hamarneh Z, Weltman M, Janko N, et al:
Mycophenolate mofetil in autoimmune hepatitis patients not
responsive or intolerant to standard therapy: The Australian
tapestry study. Hepatology. 63:817A2016.
|
|
49
|
Kostyrko O, Shumilov P and Shigoleva N:
Mycophenolate mofetil for the treatment of autoimmune hepatitis in
children. J hepatol. 64:S6402016. View Article : Google Scholar
|
|
50
|
Park SW, Um SH, Lee HA, Kim SH, Sim Y, Yim
SY, Seo YS and Ryu HS: Mycophenolate mofetil as an alternative
treatment for autoimmune hepatitis. Clin Mol Hepatol. 22:281–285.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zachou K, Gatselis NK, Arvaniti P, Gabeta
S, Rigopoulou EI, Koukoulis GK and Dalekos GN: A real-world study
focused on the long-term efficacy of mycophenolate mofetil as
first-line treatment of autoimmune hepatitis. Aliment Pharmacol
Ther. 43:1035–1047. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Haridy J, Nicoll A and Sood S:
Methotrexate therapy for autoimmune hepatitis. Clin Gastroenterol
Hepatol. Jul 12–2017.(Epub ahead of print).
|
|
53
|
Hübener S, Oo YH, Than NN, Hübener P,
Weiler-Normann C, Lohse AW and Schramm C: Efficacy of
6-mercaptopurine as second-line treatment for patients with
autoimmune hepatitis and azathioprine intolerance. Clin
Gastroenterol Hepatol. 14:445–453. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Deswal S and Srivastava A: Role of
allopurinol in optimizing thiopurine therapy in patients with
autoimmune hepatitis: A review. J Clin Exp Hepatol. 7:55–62. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Terrabuio DR, De Moraes Falcao LT, Ono SK,
Diniz MA, Carrilho FJ and Cancado E: Allopurinol is safe and
effective to achieve biochemical and histological remission in
patients with autoimmune hepatitis with incomplete therapeutic
response. J Hepatol. 64 Suppl:S4352016. View Article : Google Scholar
|
|
56
|
Marlaka JR, Papadogiannakis N, Fischler B,
Casswall TH, Beijer E and Németh A: Tacrolimus without or with the
addition of conventional immunosuppressive treatment in juvenile
autoimmune hepatitis. Acta Paediatr. 101:993–999. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Than NN, Wiegard C, Mann J, Fussel K,
Hirschfield G, Lohse AW, Adams D, Schramm C and Oo YH: Tacrolimus
is safe and effective in patients with resistant type 1 autoimmune
hepatitis. J Hepatol. 62:S805–S806. 2015. View Article : Google Scholar
|
|
58
|
Than NN, Wiegard C, Weiler-Normann C,
Weiler-Normann C, Füssel K, Mann J, Hodson J, Hirschfield GM, Lohse
AW, Adams DH, et al: Long-term follow-up of patients with difficult
to treat type 1 autoimmune hepatitis on Tacrolimus therapy. Scand J
Gastroenterol. 51:329–336. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Al Taii H, Hanouneh MA, Hanouneh I, Lopez
R, Zein N and Alkhouri N: The use of tacrolimus in refractory
autoimmune hepatitis in children and adults: A single center
experience. Scand J Gastroenterol. 52:157–158. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ytting H and Larsen FS: Everolimus
treatment for patients with autoimmune hepatitis and poor response
to standard therapy and drug alternatives in use. Scand J
Gastroenterol. 50:1025–1031. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Torisu Y, Nakano M, Takano K, Nakagawa R,
Saeki C, Hokari A, Ishikawa T, Saruta M and Zeniya M: Clinical
usefulness of ursodeoxycholic acid for Japanese patients with
autoimmune hepatitis. World J Hepatol. 9:57–63. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Efe C, Hagstrom H, Ytting H, Bhanji RA,
Müller NF, Wang Q, Purnak T, Muratori L, Werner M, Marschall HU, et
al: Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as
Second-line Therapy for Patients With Autoimmune Hepatitis. Clin
Gastroenterol Hepatol. 15:1950–1956. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Baven-Pronk AM, Coenraad MJ, van Buuren
HR, de Man RA, van Erpecum KJ, Lamers MM, Drenth JP, van den Berg
AP, Beuers UH, den Ouden J, et al: The role of mycophenolate
mofetil in the management of autoimmune hepatitis and overlap
syndromes. Aliment Pharmacol Ther. 34:335–343. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Czaja AJ: Autoimmune hepatitis: Focusing
on treatments other than steroids. Can J Gastroenterol. 26:615–620.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Czaja AJ: Drug choices in autoimmune
hepatitis: Part B-Nonsteroids. Expert Rev Gastroenterol Hepatol.
6:617–635. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kurowski J, Melin-Aldana H, Bass L, Alonso
EM and Ekong UD: Sirolimus as rescue therapy in pediatric
autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 58:e4–e6. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Chatrath H, Allen L and Boyer TD: Use of
sirolimus in the treatment of refractory autoimmune hepatitis. Am J
Med. 127:1128–1131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Ikejima K, Yaginuma R, Kon K, Aoyama T,
Uchiyama A, Yamashina S and Watanabe S: Efficacy of denosumab on
progression of osteoporosis in autoimmune liver diseases. Hepatol
(Baltimore, Md). 63:201A2016.
|
|
69
|
Gautam N, Than NN, Nizamuddin M, Adams D
and Oo YH: PTU-123 use of rituximab in resistant autoimmune
hepatitis-Birmingham experience. Gut. 63:A932014. View Article : Google Scholar
|
|
70
|
Weiler-Normann C, Schramm C, Quaas A,
Wiegard C, Glaubke C, Pannicke N, Möller S and Lohse AW: Infliximab
as a rescue treatment in difficult-to-treat autoimmune hepatitis. J
Hepatol. 58:529–534. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Dhirapong A, Yang GX, Nadler S, Zhang W,
Tsuneyama K, Leung P, Knechtle S, Ansari AA, Coppel RL, Liu FT, et
al: Therapeutic effect of cytotoxic T lymphocyte antigen
4/immunoglobulin on a murine model of primary biliary cirrhosis.
Hepatology. 57:708–715. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Killestein J: Anti-CD3 monoclonal antibody
in new-onset type 1 diabetes mellitus. N Engl J Med. 347:1116–1117.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Czaja AJ: Challenges in the diagnosis and
management of autoimmune hepatitis. Can J Gastroenterol.
27:531–539. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Lapierre P, Béland K, Yang R and Alvarez
F: Adoptive transfer of ex vivo expanded regulatory T cells in an
autoimmune hepatitis murine model restores peripheral tolerance.
Hepatology. 57:217–227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Blumenfeld HJ, Tohn R, Haeryfar SM, Liu Y,
Savage PB and Delovitch TL: Structure-guided design of an invariant
natural killer T cell agonist for optimum protection from type 1
diabetes in non-obese diabetic mice. Clin Exp Immunol. 166:121–133.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Czaja AJ: The prevention and reversal of
hepatic fibrosis in autoimmune hepatitis (Review). Aliment
Pharmacol Ther. 39:385–406. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Yellin M, Paliienko I, Balanescu A,
Ter-Vartanian S, Tseluyko V, Xu LA, Tao X, Cardarelli PM, Leblanc
H, et al: A phase II, randomized, double-blind, placebo-controlled
study evaluating the efficacy and safety of MDX-1100, a fully human
anti-CXCL10 monoclonal antibody, in combination with methotrexate
in patients with rheumatoid arthritis. Arthritis Rheum.
64:1730–1739. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Anstee QM, Concas D, Kudo H, Levene A,
Pollard J, Charlton P, Thomas HC, Thursz MR and Goldin RD: Impact
of pan-caspase inhibition in animal models of established steatosis
and non-alcoholic steatohepatitis. J Hepatol. 53:542–550. 2010.
View Article : Google Scholar : PubMed/NCBI
|
